Peer-influenced content. Sources you trust. No registration required. This is HCN.
PracticeUpdate
The authors evaluated the treatment approaches and outcomes of 110 patients with primary plasma cell leukemia (pPCL) in this retrospective study . Higher complete response rates were associated with treatment with bortezomib, lenalidomide, and dexamethasone (VRd) or daratumumab-based quadruplets (DBQ) and autologous stem-cell transplantation. Patients who received VRd/DBQ had better outcomes than those who received other bortezomib-based combinations or standard chemotherapy.
Hematology April 10th 2023
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS